Skip to main content
. 2019 Feb 28;24(Suppl 1):S42–S52. doi: 10.1634/theoncologist.2019-IO-S1-s04

Figure 3.

image

Only some patients who show a better response to the combination than treatment with a single agent will obtain clinical benefits from radioimmunotherapy. Most patients will be overtreated by the combination. A fundamental challenge is to identify a method to accurately identify patients who will derive a benefit from the combination.Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.